New RSV vaccine trial aims to protect older adults
NCT ID NCT07582796
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new vaccine against respiratory syncytial virus (RSV) in adults. Phase I includes adults 18 and older to check safety of different doses. Phase II focuses on adults 60 and older to see how well the vaccine triggers an immune response and how safe it is. The vaccine uses a recombinant protein made in CHO cells with an adjuvant to boost immunity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zigong Center for Disease Control and Prevention
RECRUITINGZigong, Sichuan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Nasal spray vaccine aims to shield children from RSV
- Inhaled interferon could be new weapon against severe RSV in young children
- New oral pill aims to fight RSV in adults
- New antiviral pill aims to shorten RSV symptoms in vulnerable adults
- New rapid test could spot flu and RSV in minutes at your local clinic
- Experimental 'Storm Stopper' therapy tested for COVID-19, flu, and RSV